AyuVis Research, Inc.
Tuesday, February 27, 2024
Plymouth
Inflammation
AyuVis is pioneering novel small molecule immunotherapies to prevent/treat inflammatory and infectious diseases based on a platform technology of macrophage modulation for a balanced immune response. An IND has been approved by the FDA in Jan 2024 for the lead candidate, AVR-48, to initiate a Phase 1 HAV clinical trial. AVR-48 has been granted Orphan Drug and Rare Pediatric Disease Designations for the prevention of bronchopulmonary dysplasia in preterm infants. We are first targeting a rare disease for high impact and a faster path to commercialization. The Phase 1 will also apply to follow-on respiratory conditions with unmet need, including ARDS and ventilator-associated pneumonia. Validated in extensive preclinical research, these immunotherapies are proven safe, to prevent organ damage, promote new cell growth, reduce mortality, and eliminate MDR bacteria via phagocytosis. Other therapeutic areas that can be addressed include ocular, renal, skin, and complicated infections/sepsis.
State
Texas
Country
United States
Website
http://www.ayuvis.com
CEO/Top Company Official
Suchismita Acharya, PhD - CEO
Lead Product in Development
AVR-48, a small molecule immunotherapy
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
Six unlicensed assets
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}